The GLP-1 Research Hub is a curated collection of educational resources, compound profiles, and published research summaries focused on glucagon-like peptide-1 (GLP-1) receptor agonists and related compounds. This hub is updated regularly as new research is published.
How to Use This GLP-1 Research Hub
Use this GLP-1 research hub to compare compounds by mechanism, regulatory status, and evidence level before opening an individual profile. Start with the compound database for a broad index, then follow the linked research articles for deeper literature context. Clinical trials, animal studies, and mechanistic findings are labeled separately because they support different conclusions. This hub also distinguishes approved medicines from investigational analogs, helping readers understand what is established, what is still being studied, and where important evidence gaps remain. It is an educational research starting point, not a dosing guide or treatment recommendation.
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally secreted by intestinal L-cells in response to food intake. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers to reduce appetite. GLP-1 receptor agonists are synthetic compounds designed to mimic or enhance this signaling — and they represent one of the most active areas of metabolic research in the past decade.
GLP-1 Compound Profiles
Each compound profile includes mechanism of action, published research summary, evidence levels, and study citations. Explore the database for detailed profiles:
- Semaglutide — GLP-1 RA approved for type 2 diabetes and weight management (Ozempic, Wegovy)
- Liraglutide — First GLP-1 RA approved for obesity management (Saxenda)
- Tirzepatide — Dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound)
- Cagrilintide — Amylin analog in combination trials with semaglutide
- Retatrutide — Triple receptor agonist (GLP-1/GIP/glucagon) in Phase III trials
- View all GLP-1 related compounds →
Key Research Areas
Metabolic function: GLP-1 receptor agonists have been studied extensively in type 2 diabetes and obesity management. The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) represent landmark clinical research programs with large, well-controlled datasets. Cardiovascular outcomes: Multiple large cardiovascular outcomes trials (LEADER, SUSTAIN-6, SELECT) have examined GLP-1 RA effects on MACE (major adverse cardiovascular events). Neurological research: GLP-1Rs are expressed in the brain, and preclinical research has examined GLP-1 agonism in neuroinflammation, neuroprotection, and Alzheimer’s disease models. Renal protection: Clinical data suggests GLP-1 receptor agonists may have nephroprotective effects, an active area of investigation. Reproductive biology: Emerging research examines GLP-1R expression in reproductive tissue — see our fertility research overview.
Understanding the Research
GLP-1 receptor agonists span a unique range — from fully FDA-approved pharmaceutical drugs (semaglutide, tirzepatide, liraglutide) to investigational analogs still in preclinical or early clinical stages. This hub covers both, with clear labeling of regulatory status for each compound.
Use the compound database to search and filter compounds by research area, evidence level, and mechanism. Visit the calculators section for reconstitution and lab math tools.
For primary literature, browse PubMed’s GLP-1 receptor agonist research results and compare trial design, endpoints, and follow-up with the evidence summary provided here.
All content on this hub is for educational and research reference purposes only. Nothing here constitutes medical advice, a treatment recommendation, or an endorsement of any compound for human use.
Additional GLP-1 Compound Detail & Research
Key Compounds in This Class
Semaglutide
GLP-1 selective agonist. FDA-approved as Ozempic (T2D) and Wegovy (obesity). Studied in SUSTAIN and STEP trials. Weekly injection or daily oral formulation (Rybelsus).
Tirzepatide
Dual GIP/GLP-1 agonist. FDA-approved as Mounjaro (T2D) and Zepbound (obesity). Studied in SURPASS and SURMOUNT trials. Head-to-head vs semaglutide in SURMOUNT-5.
Liraglutide
Daily injection GLP-1 agonist. FDA-approved as Victoza (T2D) and Saxenda (obesity). First-generation agent with extensive clinical data. Daily dosing vs weekly semaglutide.
Latest GLP-1 Research Articles
Intermittent Fasting + GLP-1 Biology
Fasting upregulates endogenous GLP-1. Here’s the mechanistic overlap and what the research shows.
Tirzepatide vs Semaglutide: Head-to-Head Research
The SURMOUNT-5 trial gave us the first direct RCT comparison. Here’s what the data shows.
Semaglutide: What the Clinical Data Actually Shows
SUSTAIN, STEP, and SELECT trials broken down — mechanisms, outcomes, and what the data actually shows.